ALK-Abello A/S/€ALKB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About ALK-Abello A/S
ALK-Abelló A/S is a Danish company specializing in the development and production of allergy immunotherapy products. The company operates within the pharmaceutical industry, providing allergy treatments that include tablets, injections, and drops. Notably, ALK-Abelló focuses on allergy immunotherapy for respiratory allergies, such as allergies to grass, tree pollen, house dust mites, and animal dander. Headquartered in Hørsholm, Denmark, ALK-Abelló serves a global market with a significant presence in Europe and North America. The company's strategic focus on research and development in allergy solutions and its specialized product portfolio underscore its commitment to addressing a critical niche in the healthcare sector.
Ticker
€ALKB
Sector
Primary listing
XGAT
Employees
2,613
Headquarters
Horsholm, Denmark
Website
ALK-Abello A/S Metrics
BasicAdvanced
€6.2B
38.34
€0.72
0.60
-
Price and volume
Market cap
€6.2B
Beta
0.6
52-week high
€31.70
52-week low
€17.49
Average daily volume
8.1K
Financial strength
Current ratio
3.381
Quick ratio
1.941
Long term debt to equity
5.508
Total debt to equity
6.486
Interest coverage (TTM)
53.68%
Profitability
EBITDA (TTM)
254.239
Gross margin (TTM)
67.24%
Net profit margin (TTM)
18.96%
Operating margin (TTM)
26.36%
Effective tax rate (TTM)
26.79%
Revenue per employee (TTM)
€323,820
Management effectiveness
Return on assets (TTM)
12.02%
Return on equity (TTM)
20.26%
Valuation
Price to earnings (TTM)
38.335
Price to revenue (TTM)
7.265
Price to book
7.22
Price to tangible book (TTM)
9.94
Price to free cash flow (TTM)
31.474
Free cash flow yield (TTM)
3.18%
Free cash flow per share (TTM)
0.88
Growth
Revenue change (TTM)
14.00%
Earnings per share change (TTM)
46.74%
3-year revenue growth (CAGR)
11.85%
10-year revenue growth (CAGR)
9.41%
3-year earnings per share growth (CAGR)
52.92%
10-year earnings per share growth (CAGR)
11.94%
10-year dividend per share growth (CAGR)
20.40%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ALK-Abello A/S stock?
ALK-Abello A/S (ALKB) has a market cap of €6.2B as of March 20, 2026.
What is the P/E ratio for ALK-Abello A/S stock?
The price to earnings (P/E) ratio for ALK-Abello A/S (ALKB) stock is 38.34 as of March 20, 2026.
Does ALK-Abello A/S stock pay dividends?
No, ALK-Abello A/S (ALKB) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next ALK-Abello A/S dividend payment date?
ALK-Abello A/S (ALKB) stock does not pay dividends to its shareholders.
What is the beta indicator for ALK-Abello A/S?
ALK-Abello A/S (ALKB) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.